NCT01865617
- Conditions
- CD19-Positive Neoplastic Cells Present, Chronic Disease, Disease Attributes, +32 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Clinical trial condition
Refractory Mantle Cell Lymphoma
Explore clinical trials studying Refractory Mantle Cell Lymphoma. Study availability and eligibility vary by location and protocol.
41 public trials
8 recruiting studies
Refractory Mantle Cell Lymphoma trial results
Completed
Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
NCT02736617
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- OHSU Knight Cancer Institute Portland, Oregon, United States
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +38 more
- Locations
-
- Presbyterian - Saint Lukes Medical Center - Health One Denver, Colorado, United States
- Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
- Mayo Clinic in Rochester Rochester, Minnesota, United States
- Hackensack University Medical Center Hackensack, New Jersey, United States
NCT01921387
- Conditions
- Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +18 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
NCT00723099
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, +63 more
- Locations
-
- University of Colorado Hospital Aurora, Colorado, United States
- Colorado Blood Cancer Institute Denver, Colorado, United States
- LDS Hospital Salt Lake City, Utah, United States
- VA Puget Sound Health Care System Seattle, Washington, United States
Completed
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT02950220
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Blood Protein Disorders, Burkitt Lymphoma, +46 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Completed
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
NCT01897012
- Conditions
- Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +36 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
NCT01719250
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +15 more
- Locations
-
- Mayo Clinic Rochester, Minnesota, United States
Active, Not Recruiting
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT01880567
- Conditions
- CCND1 Positive, CCND2 Positive, CCND3 Positive, +14 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
NCT01695941
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +12 more
- Locations
-
- Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, United States
- Montefiore Medical Center-Einstein Campus The Bronx, New York, United States
- Montefiore Medical Center - Moses Campus The Bronx, New York, United States
- Fox Chase Cancer Center Philadelphia, Pennsylvania, United States